BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.18 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)

May 19, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens ↗

May 16, 2025

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.

Via Stocktwits

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover ↗

May 16, 2025

Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children.

Via Investor's Business Daily

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress

May 16, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the...

Via StockStory

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗

May 14, 2025

BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, solid financial health, and reasonable growth prospects, making it a candidate for value investors.

Via Chartmill

1 Healthcare Stock with Competitive Advantages and 2 to Brush Off

May 09, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

May 07, 2025

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

May 07, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta...

Via StockStory

Topics Artificial Intelligence

10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know ↗

May 05, 2025

Via Benzinga

A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings ↗

May 02, 2025

Via Benzinga

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

May 01, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s...

Via StockStory

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

April 30, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence World Trade

2 Cash-Producing Stocks with Exciting Potential and 1 to Question

April 27, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question

April 22, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is an undervalued gem with solid fundamentals. ↗

April 19, 2025

BIOMARIN PHARMACEUTICAL INC has caught the attention as a great value stock. NASDAQ:BMRN excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

April 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...

Via StockStory

Topics Artificial Intelligence

6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility ↗

April 11, 2025

Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.

Via The Motley Fool

Topics Government Stocks World Trade

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

April 03, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...

Via StockStory

Topics Artificial Intelligence

BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients ↗

April 02, 2025

BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a regulatory submission for label expansion.

Via Benzinga

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction ↗

March 27, 2025

Stock market downturns are traditionally the ideal time to go shopping for bargains.

Via The Motley Fool

2 Reasons to Like BMRN (and 1 Not So Much)

March 26, 2025

Since September 2024, BioMarin Pharmaceutical has been in a holding pattern, floating around $70.24.

Via StockStory

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

March 20, 2025

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

1 Healthcare Stock to Target This Week and 2 to Turn Down

March 11, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.